Flexeril Does Not Help with Spasticity
Flexeril (cyclobenzaprine) is NOT effective for spasticity and should not be used for this indication. The FDA label explicitly states that "cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease" 1. This is a critical distinction that is often overlooked in clinical practice.
Understanding the Key Distinction
Cyclobenzaprine is classified as an antispasmodic agent for acute musculoskeletal pain, not an antispasticity agent for upper motor neuron syndromes 2. These are fundamentally different conditions:
- Muscle spasm (what Flexeril treats): Peripheral musculoskeletal conditions with acute, painful muscle contractions
- Spasticity (what Flexeril does NOT treat): Velocity-dependent hyperactivity of tonic stretch reflexes from upper motor neuron damage, as seen in stroke, spinal cord injury, cerebral palsy, or multiple sclerosis 3
Evidence-Based Medications for Spasticity
When treating spasticity that causes pain, poor hygiene, or decreased function, the recommended oral medications are 3:
First-line oral agents:
- Tizanidine - particularly for chronic stroke patients
- Baclofen - has documented efficacy though may cause sedation
- Dantrolene - limited trial data but fewer cognitive side effects
NOT recommended:
- Diazepam or benzodiazepines - contraindicated during stroke recovery due to deleterious effects on recovery and sedation 3
- Cyclobenzaprine - no evidence of efficacy for spasticity 1, 4
Treatment Algorithm for Spasticity
Follow this stepwise approach 3:
Start with non-pharmacological interventions:
- Antispastic positioning
- Range of motion exercises (several times daily)
- Stretching (at least 20 minutes per zone)
- Splinting or serial casting
Add oral medications if spasticity causes:
- Pain
- Poor skin hygiene
- Decreased function
- Choose: tizanidine, baclofen, or dantrolene
Consider targeted interventions:
- Botulinum toxin injections for localized upper or lower limb spasticity (Class I recommendation) 5
- Phenol/alcohol blocks for selected patients
For refractory cases:
- Intrathecal baclofen (can be considered as early as 3-6 months post-stroke) 5
- Neurosurgical procedures (selective dorsal rhizotomy, dorsal root entry zone lesions)
Common Clinical Pitfall
The most common error is prescribing cyclobenzaprine for spasticity because it's labeled a "muscle relaxant." This stems from confusion between antispasmodic and antispasticity agents 2. While cyclobenzaprine has fair evidence for acute musculoskeletal conditions like back pain 4, it has no mechanism of action on the central pathways that cause spasticity and will not provide benefit 1.
Why Cyclobenzaprine Doesn't Work for Spasticity
Cyclobenzaprine works primarily at the brainstem level for muscle spasms, not on the spinal reflex excitability that characterizes spasticity 2. Effective antispasticity medications work by modulating neurotransmitters (GABA, glycine, glutamate) at the cortico-spinal level to decrease spinal reflex excitability 6.
Recent comparative data confirms that among ED patients with acute musculoskeletal pain, cyclobenzaprine showed no superiority over placebo when combined with NSAIDs 7, and it carries a higher adverse effect profile including significant CNS sedation 8, 7.